Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
10
×
boston
10
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
national top stories
fda
deals
san francisco blog main
rare disease drugs
roche
alexion pharmaceuticals
avapritinib
blueprint medicines
dyne therapeutics
eli lilly
gene therapy
genentech
investing
life science
medullary thyroid cancer
myotonic dystrophy type 1
non-small cell lung cancer
novartis
pralsetinib
san diego blog main
san francisco top stories
selpercatinib
thyroid cancer
akouos
ally bridge group
alnylam pharmaceuticals
amyotrophic lateral sclerosis (als)
astellas pharma
astellas pharmaceuticals
atlas venture
audentes therapeutics
autoimmune disorders
What
drug
10
×
medicines
fda
genetic
ipo
therapeutics
approval
muscle
biotech
blueprint
cancer
candidate
company
developing
disease
diseases
dyne
lead
long
medical
million
pharma
pharmaceuticals
raised
rare
ret
roche
team
address
affects
ago
alternative
americans
analysis
approved
approves
autoimmune
bio
biotechs
brexanalone
Language
unset
Current search:
drug
×
biotech
×
boston
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges